Neurogene
Arvind Sreedharan is a seasoned executive in the biotech and pharmaceutical industries, currently serving as Senior Vice President of Business Operations at Neurogene Inc. since September 2018, where the focus is on developing genetic medicines for rare neurological diseases. Prior to this role, Arvind held several key positions at AveXis, Inc., including Vice President of US Commercial Operations during its acquisition by Novartis and Vice President of Business Operations, contributing to innovative gene therapies for spinal muscular atrophy. Additional experiences include serving as Vice President of Marketing at Auspex Pharmaceuticals, Director of Marketing at Lundbeck, and various roles at Abbott Laboratories and Novartis, establishing a solid foundation in marketing and operations within the neuroscience field.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.